Mark D. Lindsley

Dr. Mark D. Lindsley


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2001 in Journal of Clinical Microbiology
Verified
Journal Article
Closed access
PDF file
MLMark D. Lindsley
Mark D. Lindsley
SHSteven F. Hurst
Steven F. Hurst
NINaureen J. Iqbal
Naureen J. Iqbal
CMChristine J. Morrison
Christine J. Morrison
Specific oligonucleotide probes were developed to identify medically important fungi that display yeast-like morphology in vivo. Universal fungal primers ITS1 and ITS4, directed to the conserved regions of ribosomal DNA, were used to amplify DNA fromHistoplasma capsulatum,Blastomyces dermatitidis,Coccidioides immitis,Paracoccidioides brasiliensis,Penicillium marneffei,Sporothrix schenckii,Cryptococcus neoformans, fiveCandidaspecies, andPneumocystis carinii. Specific oligonucleotide probes to identify these fungi, as well as a probe to detect all dimorphic, systemic pathogens, were developed. PCR amplicons were detected colorimetrically in an enzyme immunoassay format. The dimorphic probe hybridized with DNA fromH.capsulatum,B.dermatitidis,C.immitis,P.brasiliensis, andP.marneffeibut not with DNA from nondimorphic fungi. Specific probes forH.capsulatum,B.dermatitidis,C.immitis,P.brasiliensis,P.marneffei,S.schenckii,C.neoformans, andP.cariniihybridized with homologous but not heterologous DNA. Minor cross-reactivity was observed for theB.dermititidisprobe used againstC.immitisDNA and for theH.capsulatumprobe used againstCandida albicansDNA. However, theC.immitisprobe did not cross-react withB.dermititidisDNA, nor did the dimorphic probe hybridize withC.albicansDNA. Therefore, these fungi could be differentiated by a process of elimination. In conclusion, probes developed to yeast-like pathogens were found to be highly specific and should prove to be useful in differentiating these organisms in the clinical setting.

18 August 2019 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DCDiego H. Caceres
Diego H. Caceres
MKMartha Knuth
Martha Knuth
GDGordana Derado
Gordana Derado
MLMark D. Lindsley
Mark D. Lindsley
Histoplasmosis is an important cause of mortality in people with advanced HIV, especially in countries with limited access to diagnostic assays. Histoplasmosis can be diagnosed using culture, histopathology, and antibody, antigen, and molecular assays. Several factors may affect the analytical performance of these laboratory assays, including sample type, clinical stage of the disease, and previous use of antifungal treatment, among others. Here we describe the results of a systematic literature review, followed by a meta-analysis of the analytical performances of the diagnostic laboratory assays employed. Our initial search identified 1631 references, of which 1559 references were excluded after title and abstract screening, leaving 72 references identified as studies relevant to the validation of histoplasmosis diagnostic assays. After evaluating the full text, 30 studies were selected for final review, including one paper not identified in the initial search. The meta-analysis for assay analytical performance shows the following results for the overall sensitivity (Sen) and specificity (Spe) of the various methods evaluated: Culture, Sen 77% (no data for specificity calculation); antibody detection assays, Sen 58%/Spe 100%; antigen detection assays, Sen 95%/Spe 97%; and DNA detection assays (molecular), Sen 95%/Spe 99%. Of the 30 studies reviewed, nearly half (n = 13) evaluated Histoplasma antigen assays, which were determined to be the most accurate methodology for diagnosis of progressive disseminated histoplasmosis in advanced HIV (inverse of the negative likelihood ratio was 13.2). Molecular assays appear promising for accurate diagnosis of histoplasmosis, but consensus on exact techniques is needed. Cultures showed variable sensitivity related to sample type and laboratory handling. Finally, antibody assays presented high specificity but low sensitivity. This poor sensitivity is most likely due the highly immunosuppressed state of this patient population. Diagnostic assays are crucial for accurate diagnosis of progressive disseminated histoplasmosis (PDH) with advanced HIV disease.

18 October 2019 in Mycoses
Verified
Journal Article
Closed access
PDF file
DCDiego H. Caceres
Diego H. Caceres
BGBeatriz L. Gómez
Beatriz L. Gómez
ATAngela M. Tobón
Angela M. Tobón
TCTom M. Chiller
Tom M. Chiller
MLMark D. Lindsley
Mark D. Lindsley

24 September 2021 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DCDiego H. Caceres
Diego H. Caceres
BGBeatriz L. Gómez
Beatriz L. Gómez
ÁTÁngela María Tobón
Ángela María Tobón
MMMelissa Minderman
Melissa Minderman
NBNicole Bridges
Nicole Bridges
MLMark D. Lindsley
Mark D. Lindsley
Histoplasmosis is a major cause of mortality in people living with HIV (PLHIV). Rapid methods to diagnose Histoplasma capsulatum disease could dramatically decrease the time to initiate treatment, resulting in reduced mortality. The aim of this study was to validate a MiraVista® Diagnostics (MVD) Histoplasma urine antigen lateral flow assay (MVD LFA) for the detection of H. capsulatum antigen (Ag) in urine and compare this LFA against the MVista® Histoplasma Ag quantitative enzyme immunoassays (MVD EIA). We assessed the MVD LFA using a standardized reference panel of urine specimens from Colombia. We tested 100 urine specimens, 26 from PLHIV diagnosed with histoplasmosis, 42 from PLHIV with other infectious diseases, and 32 from non-HIV infected persons without histoplasmosis. Sensitivity and specificity of the MVD LFA was 96%, compared with 96% sensitivity and 77% specificity of the MVD EIA. Concordance analysis between MVD LFA and the MVD EIA displayed an 84% agreement, and a Kappa of 0.656. The MVD LFA evaluated in this study has several advantages, including a turnaround time for results of approximately 40 min, no need for complex laboratory infrastructure or highly trained laboratory personnel, use of urine specimens, and ease of performing.

11 May 2023 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
DCDiego H. Caceres
Diego H. Caceres
BGBeatriz L. Gómez
Beatriz L. Gómez
ÁTÁngela María Tobón
Ángela María Tobón
ARAngela Restrepo
Angela Restrepo
TCTom M. Chiller
Tom M. Chiller
PVPaul Verweij
Paul Verweij
Histoplasmosis, caused by the thermally dimorphic fungus Histoplasma spp., is a disease with a broad clinical spectrum, presenting from asymptomatic/flu-like symptoms to progressive disseminated disease in people with immunosuppression. In recent years, the concept of histoplasmosis as a disease restricted to the American continent has changed, as now histoplasmosis is reported in many regions around the world. In Latin America, histoplasmosis represents a threat, especially in people with advanced HIV disease (AHD). Diagnosis of histoplasmosis in people living with HIV (PLHIV) is challenging due to the low index of suspicion of the disease, non-specificity of signs and symptoms, and limited access to specific laboratory testing, while the diagnostic delay is significantly associated with mortality. In the last decade, novel diagnostic tests have been developed for the rapid detection of histoplasmosis, such as commercial kits for antigen detection. Furthermore, advocacy groups were created that presented histoplasmosis as a public health problem, with emphasis on patients at risk of progressive disseminated disease. This review aims to discuss the impact of histoplasmosis associated with AHD in Latin America and the strategies employed to tackle histoplasmosis, from the implementation of laboratory testing to disease advocacy and public health interventions.

1 October 2015 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
MLMark D. Lindsley
Mark D. Lindsley
YAYoonJi Ahn
YoonJi Ahn
OMOrion McCotter
Orion McCotter
LGLalitha Gade
Lalitha Gade
SHSteven F. Hurst
Steven F. Hurst
ALAnastasia P. Litvintseva
Anastasia P. Litvintseva
Coccidioidomycosis (CM), a serious life-threatening fungal infection endemic to arid regions of the western United States and Mexico, can be challenging to diagnose in a timely manner. Commercially developed enzyme immunoassays (EIAs) (from Meridian Biosciences and Immuno-Mycologics [IMMY]) have provided faster, simpler means for serodiagnosis; however, independent evaluations have questioned EIA specificity, particularly IgM-positive/IgG-negative results. This study was conducted to evaluate EIA specificity among persons residing in Puerto Rico (n= 534), where CM is not endemic (who were not likely to have been exposed toCoccidioidesspp.), compared to blood bank donors residing in Arizona (n= 1,218), where CM is endemic. Upon comparing serum reactivity between Puerto Rico and Arizona, the Meridian EIA showed a significant difference in IgG reactivity (0.37% versus 3.6%;P< 0.001) but not IgM reactivity (3.4% versus 2.4%;P= 0.31). No IgM-/IgG-reactive sera were detected among sera from Puerto Rico, compared to 7 (0.57%) sera from Arizona. Similar results were observed using the IMMY EIA, although significantly (P= 0.03) fewer IgM-reactive sera from Arizona were observed, compared to the Meridian EIA. EIA-reactive sera were also evaluated by immunodiffusion before and after 3- to 4-fold concentration of the sera. These results demonstrate that elevated IgG EIA reactivity is present in sera from healthy individuals in regions of endemicity and that IgM EIA reactivity observed in sera from individuals residing outside regions of endemicity is most likely nonspecific. Other criteria, including clinical and microbiological evaluations, should be taken into account when interpreting results from surveillance studies and other reporting measures.